Deep Bio Inc.

🌟 Deep Bio Inc.'s Schedule for the Second Half of 2024! 🌟 We are excited to share that Deep Bio Inc. will be showcasing our pioneering AI-driven cancer diagnostics at several major conferences in the latter half of 2024. Here’s where you can find us: 📅 September 7-11, 2024 European Congress of Pathology (ECP) - Florence, Italy 📅 September 15-17, 2024 Digital Diagnostic Summit - Park City, UT, USA 📅 October 10-12, 2024 DINNO 2024 - Seoul, S.Korea 📅 November 3-5, 2024 Pathology Visions 2024 (DPA) - Orlando, FL, USA 📅 December 11-12, 2024 Digital Pathology & AI Congress: Europe - London, UK We invite you to visit our booth, and engage in discussions about the future of cancer diagnostics. Let's connect, collaborate, and pave the way for a brighter future together! #DeepBioInc #AIinHealthcare #CancerDiagnostics #HealthcareInnovation #MedicalConferences

Wishing You a Joyous Chuseok! 🌕🍂 As we approach Chuseok, the Korean Thanksgiving holiday, we at Deep Bio would like to extend our warmest wishes to you and your loved ones. Chuseok represents a time of gratitude, reflection, and celebration with family and friends. It is an opportunity to give thanks for the many blessings we enjoy. We hope this festive season brings you joy, peace, and prosperity. From all of us at Deep Bio, happy Chuseok!

🚀 Join us at the Digital Diagnostic Summit for a groundbreaking presentation: "ADVANCING AI IN PROSTATE PATHOLOGY: Developing Reporting Templates for Enhanced Diagnostic Precision". 🎤 Presented by: Grant Carlson | Chief Commercial Officer Deep Bio Inc. We’re addressing some of the biggest challenges in pathology reporting, including: - The time-consuming reliance on multiple tools for data entry and report generation. - Populate diagnostic reports with AI-enabled measurements and scores. - Streamlining workflows to ensure pathologists can focus on delivering the best patient care. Our new AI-driven reporting templates not only enhance diagnostic precision but also transform how pathologists work, making processes faster and more reliable. Don't miss this opportunity to learn how we're shaping the future of pathology reporting! #HealthcareInnovation #Pathology #AIinHealthcare #PatientCare

Deep Bio Inc. wraps up its time at #ECP2024 in Florence Italy!

🌟 Exciting News: Deep Bio and Roche Collaborate to Drive AI-Powered Innovations in Digital Pathology! 🌟 We are thrilled to announce a strategic collaboration between Deep Bio and Roche to integrate Deep Bio’s cutting-edge AI algorithms into Roche’s navify® Digital Pathology platform. Together, we aim to enhance diagnostic precision and streamline pathology workflows. DeepDx Prostate, an extensively validated AI solution for prostate cancer diagnosis, provides Gleason grading, tissue and tumor measurements, and more, now all within the navify® platform. This collaboration reflects Deep Bio’s ongoing commitment to advancing cancer diagnostics and elevating patient outcomes globally. 👉 Learn more: www.deepbio.co.kr/media #AIPoweredHealthcare #DigitalPathology #CancerDiagnostics #DeepBio #Roche #HealthcareInnovation #ProstateCancer

Deep Bio Inc. Participates in CancerX Summit in Washington, D.C. We are thrilled to share that Deep Bio, an AI-driven digital pathology company, recently participated in the CancerX Member Summit on September 4-5, 2024, in Washington, D.C. Our CEO, Sun Woo Kim, had the honor of joining global leaders and senior U.S. government officials in vital discussions focused on accelerating cancer eradication efforts. As part of the U.S. CancerX Moonshot initiative, CancerX brings together experts across various sectors to drive innovation in cancer treatment, research, and data interoperability. Our participation underscored Deep Bio’s commitment to advancing strategic initiatives that shape the future of cancer care. We’re excited about this project and look forward to continuing our work toward realizing more cancer conquest projects and improving patient outcomes worldwide. #CancerX #CancerMoonshot #AIinHealthcare #DigitalPathology #CancerResearch #DeepBio

Deep Bio Inc. looks forward to meeting with you in Florence!

🚀 Deep Bio and ABION Sign MOU to Revolutionize AI-Driven Cancer Diagnostics 🚀 We are thrilled to announce that Deep Bio has signed a Memorandum of Understanding (MOU) with ABION. This strategic partnership is designed to leverage our cutting-edge AI technologies to enhance cancer diagnostics and accelerate the development of life-saving treatments. Through this collaboration, ABION will integrate Deep Bio's advanced AI-driven c-MET IHC interpretation services into their clinical programs, including key pipeline assets like ABN401 (vabametkib) and ABN101. Our DeepCDx solution will play a crucial role in improving patient recruitment and identification, particularly in ABION’s ongoing combination trials involving vabametkib and lazertinib. This partnership highlights our commitment to pushing the boundaries of AI in digital pathology, enabling more precise and efficient clinical trials. Together, we are poised to make significant strides in the fight against cancer, delivering more effective and personalized treatments to patients worldwide. #AI #CancerDiagnostics #ClinicalTrials #Oncology #Innovation #DeepBio #ABION

🔬 Get ready for the 36th European Congress of Pathology! Join our exceptional team as we present our breakthroughs in digital pathology at this prestigious event. 🌟 Explore cutting-edge technologies, connect with leading experts, and discuss exciting collaboration opportunities. Reserve your spot now using QR-code. See you at #ECP2024! #DeepBio #DigitalPathology

🎗️ September is Prostate Cancer Awareness Month! 🎗️ As we mark Prostate Cancer Awareness Month this September, it's a timely reminder of the critical importance of early detection and accurate diagnosis in the fight against prostate cancer. At Deep Bio Inc., we're deeply committed to advancing these efforts through our AI-powered digital pathology solutions. Prostate cancer is one of the most common cancers affecting men, yet with early detection and precise assessment, we can dramatically improve patient outcomes. This is where innovation plays a crucial role. Our team has been at the forefront of developing AI technology that enhances the accuracy and efficiency of prostate cancer detection. By partnering closely with leading healthcare institutions, we aim to empower pathologists around the world to make faster, more accurate diagnoses. This year, we’re proud to have reached significant milestones, including the adoption of our AI models in clinical settings. These advancements are not just about improving technology—they're about ensuring that every patient receives the most accurate diagnosis possible, which can be life-changing. Our tools help detect even the most subtle signs of prostate cancer, allowing for earlier intervention and more personalized treatment plans. However, our journey is ongoing. We're continuously working to refine our technology, collaborate with medical professionals, and stay ahead of the curve in AI and digital pathology. Our goal is to contribute to a future where prostate cancer is detected earlier, assessed more precisely, and treated more effectively. As we observe Prostate Cancer Awareness Month, we encourage everyone in our network to advocate for regular screenings, stay informed about the latest advancements, and support the ongoing fight against this disease. Together, with the power of AI and our collective efforts, we can make a real difference. #ProstateCancerAwareness #AIinHealthcare #DigitalPathology #InnovationInMedicine #DeepBio